TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...

Our 2025 goal is 30 centers by the end of the year ... A subgroup analysis from the FOCUS trial presented at ESMO 2024 ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33. Operator: Good afternoon, everyone, and welcome to Personalis Third Quarter 2024 ...

Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...

WILMINGTON, Del., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage ...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in ...

An improvement of the same amount year over year increasing Cologuard, customer satisfaction and brand awareness to all time highs receiving FDA approval for Cologuard plus our next generation ...

The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...